GP9 and pulmonary arterial hypertension: Furthermore, EVs have been proposed as non-invasive biomarkers for the early detection of pulmonary arterial hypertension (PAH) in SSc, with elevated levels of platelet-derived EVs (CD42a) and immune-related markers (CD3 and CD56) indicating their involvement in disease progression and vascular dysfunction [12].